Singapore, Nov. 10 -- Edesa Biotech, Inc., a Canada-based clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, and Kyorin Pharmaceutical Co, a leading Japanese pharmaceutical company, have entered into an exclusive collaboration and license agreement for the development and commercialisation of paridiprubart in Japan.

Under the terms of the agreement, Kyorin will obtain an exclusive license to further develop and commercialiae Edesa's drug candidate, paridiprubart, in Japan, in Acute Respiratory Distress Syndrome (ARDS). Edesa will receive an upfront payment of $12 million and is eligible to receive additional development, regulatory and sales-based milestones up to a...